Hydroflumethiazide

Summary

Hydroflumethiazide (CHEMBL1763) is an approved small-molecule diuretic (ATC C03AA02); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C03AA02 (+1 more)
• Indications: 1 condition
• Chemistry: 331.3 Da · C8H8F3N3O4S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1763
Name	Hydroflumethiazide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3647
ChEBI	CHEBI:5784
ATC	C03AA02, C03AH02
Molecular formula	C8H8F3N3O4S2
Molecular weight	331.3
InChIKey	DMDGGSIALPNSEE-UHFFFAOYSA-N

SMILES: C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1

IUPAC name: 1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide

ChEBI definition: A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.

Pharmacological roles (ChEBI): diuretic, antihypertensive agent.

Also known as: Diucardin, Hidroflumetiazida, Hydrenox, Hydroflumethiazide, NSC-44627, Saluron, Hydroflumethazide, hydroflumethiazide, SID11112295, SID26747027, SID855883, HYDROFLUMETHIAZIDE

Patent coverage: 3,211 distinct patent families (12,357 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Lysine-specific demethylase 4E, Survival motor neuron protein, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Cytochrome P450 2C9, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 8 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6	Potency	1000	nM	CHEMBL_ACT_3644599
SMN1	5.35	Potency	4467	nM	CHEMBL_ACT_3907481

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).